featured
Radium-223 in Castration-Resistant Prostate Cancer With Bone Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients With Castration-Resistant Prostate Cancer and Bone Metastases: Results From a Phase 3, Double-Blind, Randomised Trial
Lancet Oncol 2014 May 15;[EPub Ahead of Print], O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, A Chodacki, P Wiechno, J Logue, A Widmark, DC Johannessen, P Hoskin, ND James, A Solberg, I Syndikus, NJ Vogelzang, CG O'Bryan-Tear, M Shan, ØS Bruland, C ParkerAdvanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.